Contract development and manufacturing organisation Recipharm has signed a long-term agreement with Sato Pharmaceutical Co. for the commercial manufacture and delivery of Emla™ Patch to Japan.
Emla™ Patch is used as a local anaesthetic product and will be launched under Sato’s ethical pharmaceuticals business area.
Recipharm’s facility in Karlskoga, Sweden, will produce and deliver to Sato. Following its successful launch in Japan, it is expected that the annual volumes of Emla™ Patch to Sato will be a significant addition to current production activity at the Karlskoga facility.
Ingela Palmkvist, General Manager at Recipharm in Karlskoga, said: “We are looking forward to the launch in Japan and cooperating with Sato in developing the business, to the benefit of both companies.”